Vertex agreed to buy Crinetics Pharmaceuticals for $10 billion in cash, its largest-ever acquisition, expanding the company beyond cystic fibrosis and adding an endocrinology platform. Crinetics’ lead is Palsonify (paltusotine) for acromegaly, along with a phase III asset for congenital adrenal hyperplasia, as Vertex targets a broader portfolio of specialty endocrine therapies.